X0306 4 2013-03-26 0001177648 ENANTA PHARMACEUTICALS INC ENTA 0001133921 SCHUHSLER HELMUT C/O TVM CAPITAL MAXIMILIANSTRASSE 35C MUNICH 2M 80539 GERMANY 1 0 1 0 Common Stock 2013-03-26 4 C 0 236065 A 236065 I See Note 5. Common Stock 2013-03-26 4 C 0 351014 A 587079 I See Note 6. Common Stock 2013-03-26 4 C 0 155316 A 742395 I See Note 5. Common Stock 2013-03-26 4 C 0 172030 A 914425 I See Note 6. Common Stock 2013-03-26 4 C 0 1006498 A 1920923 I See Note 7. Common Stock 2013-03-26 4 C 0 478247 A 2399170 I See Note 7. Common Stock 2013-03-26 4 P 0 132949 14.00 A 2532119 I See Note 7. Series C Convertible Preferred Stock 2013-03-26 4 C 0 1017442 0 D Common Stock 236065 0 I See Note 5. Series D Convertible Preferred Stock 2013-03-26 4 C 0 1130000 0 D Common Stock 351014 500000 I See Note 6. Series D Convertible Preferred Stock 2013-03-26 4 C 0 500000 0 D Common Stock 155316 0 I See Note 5. Series E Convertible Preferred Stock 2013-03-26 4 C 0 563503 0 D Common Stock 172030 3296888 I See Note 6. Series E Convertible Preferred Stock 2013-03-26 4 C 0 3296888 0 D Common Stock 1006498 0 I See Note 7. Series G-2 Convertible Preferred Stock 2013-03-26 4 C 0 2061246 0 D Common Stock 478247 0 I See Note 7. The Series C Convertible Preferred Stock automatically converted into Enanta Pharmaceuticals, Inc. ("Enanta") Common Stock on a 0.23202-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date. The Series D Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.31063-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date. The Series E Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.30529-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date. The Series G-2 Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.23202-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date. The shares are directly held by TVM Medical Ventures GmbH & Co. KG ("Medical Ventures"), the general partner of which is TVM Capital GmbH ("TVM Capital"), for which Helmut Schuhsler ("Schuhsler"), one member of the investment committee of TVM Capital, shares voting and investment authority over the shares held by Medical Ventures with the other member of the investment committee. Schuhsler disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. The shares are directly held by TVM IV GmbH & Co. KG ("TVM IV"), the managing limited partner of which is TVM IV Management GmbH & Co. KG ("TVM IV Management"), for which Schuhsler, one member of the investment committee of TVM IV Management, shares voting and investment authority over the shares held by TVM IV with the other members of the investment committee. Schuhsler disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. The shares are directly held by TVM V Life Science Ventures GmbH & Co. KG ("TVM V"), the managing limited partner of which is TVM V Life Science Ventures Management GmbH & Co. KG ("TVM V Management"), for which for which Schuhsler, one member of the investment committee of TVM V Management, shares voting and investment authority over the shares held by TVM V with the other members of the investment committee. Schuhsler disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. Includes 236,065 shares held directly by Medical Ventures. Includes 236,065 shares held directly by Medical Ventures and 351,014 shares held directly by TVM IV. Includes 391,381 shares held directly by Medical Ventures and 351,014 shares held directly by TVM IV. Includes 391,381 shares held directly by Medical Ventures and 523,044 shares held directly by TVM IV. Includes 391,381 shares held directly by Medical Ventures, 523,044 shares held directly by TVM IV and 1,006,498 shares held directly by TVM V. Includes 391,381 shares held directly by Medical Ventures, 523,044 shares held directly by TVM IV and 1,484,745 shares held directly by TVM V. Includes 391,381 shares held directly by Medical Ventures, 523,044 shares held directly by TVM IV and 1,617,694 shares held directly by TVM V. Rolf Starck by power of attorney for Helmut Schuhsler 2013-03-28